Preclinical studies have demonstrated that PAK selective inhibitors for PAK1 (FRAX597) and PAK4 (PF-3758309) suppress tumour growth and improve chemotherapy response across multiple solid tumours [24,25]. This evidence concerns the gene PAK1 and neoplasm.